未找到相关数据
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.
被引：4
作者：
Sheng, Xinan
Zhang, Cuijian
Ji, Yongpeng
Zhou, Li
Zou, Benkui
Huang, Hang
Wang, Yonghua
Yang, Kaiwei
Bai, Xue
Feng, Dan
Yang, Yong
Bian, Jiasheng
Yu, Zhixian
Niu, Haitao
Du, Peng
Fang, Jianmin
He, Zhisong
Guo, Jun
机构：
[1] Peking Univ, Dept Genitourinary Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China
[2] Peking Univ First Hosp, Beijing, Peoples R China
[3] Peking Univ Canc Hosp, Dept Urol, Beijing, Peoples R China
[4] Shandong First Med Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[5] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China
[6] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[7] Peking Univ First Hosp, Dept Urol, Beijing, Peoples R China
[8] RemeGen Co Ltd, Med Dept Oncol, Yantai, Peoples R China
[9] RemeGen Co Ltd, Yantai, Peoples R China
[10] Peking Univ, Canc Hosp, Beijing, Peoples R China
[11] Shandong Canc Hosp, Jinan, Peoples R China
[12] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.665
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文